User:Rafael Romero Becerra/Sandbox 1
From Proteopedia
(Difference between revisions)
Line 8: | Line 8: | ||
PCSK9 was first described as neural apoptosis-regulated convertase 1 (NARC-1) in studies of cerebral neuron apoptosis, suggesting that it could be implicated in the differentiation of cortical neurons <ref>DOI 10.1073/pnas.0335507100</ref>. Concomitant and following studies in patients with familiar hypercholesterolemia revealed the clinical importance of PCSK9, showing that patients with gain-of-function mutations presented increased levels of cholesterol in plasma (i.e. hypercholesterolemia) due to reduced expression of LDLRs. In contrast, loss-of-function variants of PSCK9 are associated with a reduction of LDL cholesterol levels and a lower risk of cardiovascular disease. The role of PSCK9 in LDLRs and cholesterol metabolism has been confirmed in animal models. Thus, mice overexpressing PCSK9 show a reduction in the expression of hepatic LDLRs and hypercholesterolemia, whereas knockout mice for PCSK9 present decreased levels of plasmatic LDL cholesterol because of increased expression of LDLRs <ref>DOI 10.1002/humu.20882</ref><ref>DOI 10.1146/annurev-med-042716-091351</ref>. | PCSK9 was first described as neural apoptosis-regulated convertase 1 (NARC-1) in studies of cerebral neuron apoptosis, suggesting that it could be implicated in the differentiation of cortical neurons <ref>DOI 10.1073/pnas.0335507100</ref>. Concomitant and following studies in patients with familiar hypercholesterolemia revealed the clinical importance of PCSK9, showing that patients with gain-of-function mutations presented increased levels of cholesterol in plasma (i.e. hypercholesterolemia) due to reduced expression of LDLRs. In contrast, loss-of-function variants of PSCK9 are associated with a reduction of LDL cholesterol levels and a lower risk of cardiovascular disease. The role of PSCK9 in LDLRs and cholesterol metabolism has been confirmed in animal models. Thus, mice overexpressing PCSK9 show a reduction in the expression of hepatic LDLRs and hypercholesterolemia, whereas knockout mice for PCSK9 present decreased levels of plasmatic LDL cholesterol because of increased expression of LDLRs <ref>DOI 10.1002/humu.20882</ref><ref>DOI 10.1146/annurev-med-042716-091351</ref>. | ||
+ | == Gene and synthesis of PCSK9 == | ||
+ | |||
+ | PCSK9 is the ninth known member of the mammalian subtilisin (S8) serine proprotein convertase (PC) family that carries out the proteolytic maturation of secretory proteins such as neuropeptides, prohormones and cytokines. Humans have nine different PCs that can be divided between S8A and S8B subfamilies. PCSK9 is classified in subfamily S8A <ref>DOI 10.1016/j.str.2007.04.004 </ref>. | ||
+ | |||
+ | The human gene for PCSK9 is 22 kb length and it is located in chromosome 1p32.3. It contains 11 introns and 12 exons that encode the 692 amino acids of the enzyme. The sequence of the protein is characterized by a signal sequence (amino acids 1-30), a prodomain (amino acids 31-152), and a catalytic domain, followed by a C-terminal region of 243 amino acids which is rich in cysteine and histidine residues '''Fig. 1'''. PCSK9 is mainly expressed in the liver, intestine and kidney, and it can also be in the nervous system. It is synthesized as a precursor of ~74 kDa that is processed in the endoplasmic reticulum (ER) where it undergoes cleavage of its signal peptide and intramolecular autocatalytic cleavage producing a ~60-kDa catalytic fragment. The autocatalysis of the zymogen takes place between Gln152 and Ser153 <ref>DOI 10.1016/j.abb.2003.09.011</ref>. This cleavage is necessary for transport from ER to the Golgi body and for secretion. The cleaved prodomain of ~14 kDa remains associated with the catalytic domain, which is unique to PCSK9. This facilitates protein folding, permits the mature protein to move from ER into the secretory pathway and regulates the catalytic activity of the enzyme by blocking the access to the catalytic site '''Fig. 2?''' <ref>DOI 10.1002/humu.20882</ref><ref>DOI 10.1146/annurev-med-042716-091351</ref>. | ||
+ | |||
+ | PCSK9 can be found in plasma in two forms: the mature and secreted form of ~60 kDa, and as an inactivated fragment of ~53 kDa produced by the cleavage of the mature form at the motive RFHR218↓ by other proprotein convertases, mainly furin and/or PC5/6A <ref>DOI 10.1074/jbc.M606495200</ref>. | ||
+ | In humans, PCSK9 circulates in plasma in a phosphorylated state and it has been shown that it is phosphorylated at the Ser47 and Ser688 by a Golgi casein kinase-like kinase ex vivo. This phosphorylation might be important to protect the propeptide against proteolysis <ref>DOI 10.1111/j.1742-4658.2008.06495.x</ref>. | ||
Revision as of 12:27, 27 November 2017
PCSK9: Pro-protein convertase subtilisin/kexin type 9
|
References
- ↑ Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, Basak A, Prat A, Chretien M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):928-33. Epub 2003 Jan 27. PMID:12552133 doi:http://dx.doi.org/10.1073/pnas.0335507100
- ↑ Abifadel M, Rabes JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009 Apr;30(4):520-9. doi: 10.1002/humu.20882. PMID:19191301 doi:http://dx.doi.org/10.1002/humu.20882
- ↑ Hess CN, Low Wang CC, Hiatt WR. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Annu Rev Med. 2017 Nov 2. doi: 10.1146/annurev-med-042716-091351. PMID:29095667 doi:http://dx.doi.org/10.1146/annurev-med-042716-091351
- ↑ Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 2007 May;15(5):545-52. PMID:17502100 doi:http://dx.doi.org/10.1016/j.str.2007.04.004
- ↑ doi: https://dx.doi.org/10.1016/j.abb.2003.09.011
- ↑ Abifadel M, Rabes JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009 Apr;30(4):520-9. doi: 10.1002/humu.20882. PMID:19191301 doi:http://dx.doi.org/10.1002/humu.20882
- ↑ Hess CN, Low Wang CC, Hiatt WR. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Annu Rev Med. 2017 Nov 2. doi: 10.1146/annurev-med-042716-091351. PMID:29095667 doi:http://dx.doi.org/10.1146/annurev-med-042716-091351
- ↑ Benjannet S, Rhainds D, Hamelin J, Nassoury N, Seidah NG. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem. 2006 Oct 13;281(41):30561-72. Epub 2006 Aug 15. PMID:16912035 doi:http://dx.doi.org/10.1074/jbc.M606495200
- ↑ Dewpura T, Raymond A, Hamelin J, Seidah NG, Mbikay M, Chretien M, Mayne J. PCSK9 is phosphorylated by a Golgi casein kinase-like kinase ex vivo and circulates as a phosphoprotein in humans. FEBS J. 2008 Jul;275(13):3480-93. doi: 10.1111/j.1742-4658.2008.06495.x. Epub, 2008 May 22. PMID:18498363 doi:http://dx.doi.org/10.1111/j.1742-4658.2008.06495.x
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644